2019 年冠状病毒病 (COVID-19) 患者经常会出现过度炎症综合征，从而导致不良结果。这种情况类似于肿瘤、风湿病和其他传染病中描述的继发性噬血细胞性淋巴组织细胞增多症 (sHLH)。评估潜在免疫抑制、体温、器官肿大、血细胞减少、铁蛋白、甘油三酯、纤维蛋白原和 AST 的评分系统 (HScore) 已针对 sHLH 进行了验证，最近提议用于评估 COVID-19 中的过度炎症。评估 COVID 患者中是否存在 sHLH -19 人入院治疗，并评估 Hscore 作为不良结果的预后工具。 143 名年龄在 21-100 岁之间的患者（64% 男性）因 COVID-19 入院参加了一项前瞻性研究。 HScore 是在入学 72 小时内计算的。评估住院期间 sHLH 的发生率。此外，还探讨了 HScore ≥ 130 分与机械通气需求或 60 天死亡率之间的关系。HScore 中位数为 96 (33-169)。一名患者被诊断为 SHLH（发生率为 0.7%），其 HScore 为 169。在调整年龄、性别、合并症和肥胖后，HScore ≥ 130 与复合临床结果独立相关（危险比 2.13，p = 0.022）。 sHLH 在 COVID-19 患者中并不常见。 HScore 可用于预测不良结果的风险。

Patients with Coronavirus Disease 2019 (COVID-19) frequently experience a hyperinflammatory syndrome leading to unfavorable outcomes. This condition resembles Secondary Hemophagocytic Lymphohistiocytosis (sHLH) described in neoplastic, rheumatic and other infectious diseases. A scoring system (HScore) that evaluates underlying immunosuppression, temperature, organomegaly, cytopenias, ferritin, triglycerides, fibrinogen and AST was validated for sHLH, and recently proposed to evaluate hyperinflammation in COVID-19.To assess the presence of sHLH among patients with COVID-19 admitted for hospitalization and to evaluate Hscore as a prognostic tool for poor outcomes.One hundred forty-three patients aged 21-100 years (64% males) admitted because of COVID-19 were enrolled in a prospective study. HScore was calculated within 72 hours admission. The incidence of sHLH during hospitalization was evaluated. Additionally, the relationship between a HScore ≥ 130 points and either the requirement of mechanical ventilation or 60-days mortality was explored.The median HScore was 96 (33-169). A SHLH was diagnosed in one patient (incidence 0.7%), whose HScore was 169. After adjusting for age, sex, comorbidities and obesity, HScore ≥ 130 was independently associated with the composite clinical outcome (Hazard rartio 2.13, p = 0.022).sHLH is not frequent among COVID-19 patients. HScore can be useful to predict the risk for poor outcomes.